Study guide

17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy

Key Takeaways Explain This Topic AI

For acute migraine in the ED, the American Headache Society says clinicians should offer IV metoclopramide, IV prochlorperazine or SC sumatriptan, plus dexamethasone to reduce recurrence.

Hydromorphone was far less effective than IV prochlorperazine for ED migraine in the HIT trial (2017), so opioids are not a first-line migraine treatment.

Cluster headache attacks are aborted with 100% oxygen at 12 to 15 L/min by non-rebreather mask for 15 minutes or with sumatriptan 6 mg SC.

Myasthenic crisis is treated with IVIG 2 g/kg or plasma exchange; fluoroquinolones, aminoglycosides, macrolides and IV magnesium can worsen weakness.

Corticosteroids do not help Guillain-Barré syndrome, but within 72 hours of onset they improve recovery in Bell's palsy.

Last updated: October 2026

17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy

Note

Exam scope: 2025 outline subtopic 2B7 (Pharmacotherapy for Neurology). Stroke, intracranial and subarachnoid hemorrhage, status epilepticus and traumatic brain injury are covered in Chapter 5; botulism antitoxin logistics in Section 14.3.

Dangerous Headaches First

Before treating a headache as migraine, look for red flags of a secondary cause:

  • Sudden "thunderclap" onset or the worst headache of the patient's life: subarachnoid hemorrhage (Section 5.2)
  • Fever with a stiff neck: meningitis (Section 12.1)
  • New headache after age 50, jaw claudication or visual symptoms: giant cell arteritis
  • Pregnancy or postpartum status: preeclampsia (Section 13.3) or cerebral venous thrombosis
  • Anticoagulant use, cancer, immunosuppression or papilledema
  • Several people in a household with headache: carbon monoxide (Section 9.2)

Giant cell arteritis threatens vision. The 2021 ACR/Vasculitis Foundation guideline supports starting high-dose glucocorticoids, such as prednisone 1 mg/kg/day (commonly 40 to 60 mg), without waiting for the temporal artery biopsy. Patients with visual loss usually receive IV methylprednisolone 500 to 1,000 mg daily for 3 days first.

  • Acute Migraine in the ED
  • American Headache Society Evidence Assessment (2016)
  • Recommendation Agents
  • Should offer IV metoclopramide 10 mg; IV prochlorperazine 10 mg; SC sumatriptan 6 mg
  • Should offer to prevent recurrence IV dexamethasone (commonly 10 mg)

May offer IV ketorolac, IV valproate, IV acetaminophen, IV dihydroergotamine (DHE) with an antiemetic, droperidol, chlorpromazine, and others

  • May avoid IV hydromorphone, IV morphine; IV diphenhydramine on its own (it does not add pain relief)
  • Key Drug Details

Dopamine antagonists (metoclopramide, prochlorperazine, droperidol) are the workhorses of ED migraine care. Higher metoclopramide doses (20 or 40 mg) were no better than 10 mg. Akathisia is the main adverse effect; infusing over about 15 minutes reduces it, and diphenhydramine is often given with the dose to prevent it.

Sumatriptan 6 mg SC is most useful early in an attack. Contraindications include coronary, cerebrovascular or peripheral vascular disease, uncontrolled hypertension, hemiplegic or brainstem aura, and a triptan or ergot in the past 24 hours.

Dihydroergotamine 0.5 to 1 mg IV (after an antiemetic) is effective for prolonged migraine. It must not be given within 24 hours of a triptan, in pregnancy, in vascular disease, or with strong CYP3A4 inhibitors (boxed warning for ergotism and ischemia).

Dexamethasone given once reduces moderate to severe headache recurrence over the next 72 hours (number needed to treat about 9). It does not speed initial relief.

Opioids: in the HIT trial (2017), IV hydromorphone was much less likely than IV prochlorperazine to give sustained relief, and the trial stopped early. Opioids also promote return visits and medication-overuse headache.

Greater occipital nerve block with a local anesthetic is a reasonable option for patients who cannot take, or do not respond to, the drugs above.

Pregnancy and Discharge

In pregnancy, acetaminophen and metoclopramide are preferred. Avoid valproate and DHE, and avoid NSAIDs after about 20 weeks. At discharge, warn patients about medication-overuse headache (simple analgesics on 15 or more days a month, or triptans on 10 or more days a month) and refer for preventive therapy when attacks are frequent.

Cluster Headache

Cluster attacks are severe, one-sided headaches around the eye with tearing, nasal congestion and restlessness, lasting 15 to 180 minutes.

  • 100% oxygen at 12 to 15 L/min by non-rebreather mask for 15 minutes
  • Sumatriptan 6 mg SC , or zolmitriptan nasal spray

Short courses of oral steroids or an occipital nerve block can bridge the patient until preventive treatment (commonly verapamil , with ECG monitoring for heart block) takes effect.

Myasthenia Gravis and Myasthenic Crisis

Myasthenic crisis is respiratory failure from weakness of the breathing and swallowing muscles. Infection, surgery, pregnancy and medications commonly trigger it.

Monitoring Respiratory Function

Pulse oximetry and blood gases change late. Use bedside respiratory mechanics, often remembered as the "20/30/40 rule" :

  • Vital capacity below 20 mL/kg
  • Maximal inspiratory pressure weaker than −30 cm H2O
  • Maximal expiratory pressure below 40 cm H2O

Any of these, or a declining trend, should prompt ICU care and planning for elective intubation.

Treatment

Therapy Notes

IVIG 2 g/kg divided over 2 to 5 days Similar efficacy to plasma exchange; check IgA status, watch for volume overload, kidney injury and thrombosis

Plasma exchange (about 5 exchanges) Works faster in some patients; needs central access

High-dose corticosteroids Can cause temporary worsening in the first 1 to 2 weeks, so they are usually started alongside IVIG or plasma exchange in a monitored setting

Pyridostigmine Often held while the patient is intubated because it increases secretions

Newer maintenance drugs include FcRn blockers and complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan). C5 inhibitors carry boxed warnings and REMS programs for life-threatening meningococcal infection . Treat fever in these patients as possible meningococcemia.

  • Drugs That Can Worsen Myasthenia
  • Fluoroquinolones (boxed warning), aminoglycosides , macrolides and telithromycin
  • IV magnesium
  • Beta-blockers, procainamide and quinidine
  • Hydroxychloroquine, chloroquine and quinine
  • Botulinum toxin
  • Immune checkpoint inhibitors , which can also cause new myasthenia

Intubating a patient with myasthenia: patients are relatively resistant to succinylcholine, so higher doses (such as 1.5 to 2 mg/kg) are often used. They are very sensitive to non-depolarizing agents, so expect prolonged paralysis from rocuronium and keep sugammadex available.

Guillain-Barré Syndrome (GBS)

GBS causes ascending, symmetric weakness with loss of reflexes, often after a respiratory or GI infection.

IVIG 0.4 g/kg/day for 5 days (2 g/kg total) or plasma exchange started within 2 to 4 weeks of onset speeds recovery. Combining them adds no benefit.

Corticosteroids are not effective and are not used.

Respiratory failure: use the 20/30/40 thresholds. Rapid progression, inability to cough or lift the head, and bulbar weakness predict the need for ventilation.

Dysautonomia: blood pressure and heart rate can swing widely. Treat with short-acting, titratable drugs, and use caution with drugs that cause hypotension or bradycardia.

Avoid succinylcholine because denervated muscle releases dangerous amounts of potassium (Section 4.3).

Neuropathic pain responds to gabapentinoids. Give VTE prophylaxis to patients who cannot walk.

Botulism

Botulism causes descending, symmetric paralysis that starts with the cranial nerves (double vision, drooping eyelids, slurred speech, difficulty swallowing) in an alert patient. Contact the state health department immediately: CDC releases heptavalent botulinum antitoxin for children and adults, and botulism immune globulin (BabyBIG) for infant botulism. Avoid aminoglycosides, which worsen neuromuscular blockade. Wound botulism in people who inject drugs also needs debridement.

Bell's Palsy

Bell's palsy is an acute peripheral facial nerve palsy affecting the whole half of the face, including the forehead. Rule out stroke (which spares the forehead), Lyme disease, zoster and otitis.

Oral corticosteroids started within 72 hours of onset (AAO-HNS 2013), for example prednisolone 50 mg daily for 10 days or prednisone 60 mg daily for 5 days followed by a taper.

Antivirals alone are not recommended ; adding valacyclovir to steroids is optional.

Eye protection is essential: lubricating drops by day, ointment and taping at night, to prevent corneal injury.